

DAFTAR PUSTAKA

1. Sultana ZZ, Hoque FU, Beyene J, Akhlak-UI-Islam M, Khan MHR, Ahmed S, et al. HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis. *BMC Infect Dis.* 2021;21(1):1–13.
2. Kizito E, Musaazi J, Mutesasira K, Twinomugisha F, Namwanje H, Kiyemba T, et al. Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda- a case-control study. *BMC Infect Dis.* 2021;21(1):1–7.
3. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. *Lancet Respir Med.* 2017;5(4):291–360.
4. World Health Organization (WHO). *Global Tuberculosis Report.* Geneva. 2022. 104–16 p.
5. Soeroto AY, Pratiwi C, Santoso P, Lestari BW. Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: A retrospective cohort study. *PLoS One.* 2021;16(2):1–13.
6. Kementrian Kesehatan Republik Indonesia. *Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia.* 2020. h 7–35.
7. Torres NMC, Rodriguez JJQ, Andrade PSP, Arriaga MB, Netto EM. Factors predictive of the success of tuberculosis treatment: A systematic review with meta-analysis. *PLoS One.* 2019;14(12):1–24.
8. Soeroto AY, Lestari BW, Santoso P, Chaidir L, Andriyoko B, Alisjahbana B, et al. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study. *PLoS One.* 2019;14(2):1–16.
9. Belachew T, Yaheya S, Tilahun N, Gebrie E, Seid R, Nega T, et al.

Multidrug-Resistant Tuberculosis Treatment Outcome and Associated Factors at the University of Gondar Comprehensive Specialized Hospital: A Ten-Year Retrospective Study. *Infect Drug Resist.* 2022;2891–9.

10. Kristina K, Lolong DB, Sari DP. Pemanfaatan Metode Tes Cepat Molekuler (XPRT MTB/RIF) Di Kabupaten Sorong Tahun 2014-2018. *Bul Penelit Sist Kesehat.* 2020;23(3):154–60.
11. World Health Organization (WHO). Implementing The End TB Strategy. *Antimicrob Agents Chemother.* 2015;58(12):7250–7.
12. Merk H, Ködmön C, van der Werf MJ. Will we reach the sustainable development goals target for tuberculosis in the European Union/European economic area by 2030. *Eurosurveillance.* 2019;24(12):2015–8.
13. Soeroto AY, Nurhayati RD, Purwiga A, Lestari BW, Pratiwi C, Santoso P, et al. Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia. *PLoS One.* 2022;5–11.
14. Tola H, Holakouie-Naieni K, Mansournia MA, Yaseri M, Gamtesa DF, Tesfaye E, et al. National treatment outcome and predictors of death and treatment failure in multidrug-resistant tuberculosis in Ethiopia: A 10-year retrospective cohort study. *BMJ Open.* 2021;11(8):1–9.
15. Jaleta KN, Gizachew M, Gelaw B, Tesfa H, Getaneh A, Biadgo B. Rifampicin-resistant Mycobacterium tuberculosis among tuberculosis-presumptive cases at University of Gondar hospital, northwest Ethiopia. *Infect Drug Resist.* 2017;10:185–92.
16. Pangaribuan L, Kristina K, Perwitasari D, Tejayanti T, Lolong DB. Faktor-Faktor yang Mempengaruhi Kejadian Tuberkulosis pada Umur 15 Tahun ke Atas di Indonesia. *Bul Penelit Sist Kesehat.* 2020;23(1):15–35.
17. World Health Organization (WHO). WHO consolidated guidelines on

tuberculosis. WHO Press. 2022. 98 p.

18. Singh A, Gupta AK, Singh S. Molecular mechanisms of drug resistance in *Mycobacterium tuberculosis*: Role of nanoparticles against multi-drug-resistant tuberculosis (MDR-TB). *NanoBioMedicine*. :285–314.
19. Fathiyah Isbaniah, Burhan E, Sinaga BY, Yanifitri DB, Handayani D, Harsini, et al. Tuberkulosis Pedoman Diagnosis dan Penatalaksanaan di Indonesia. PDPI. 2021. 1–78 p.
20. Kemenkes P2PL. Temukan TB Obati Sampai Sembuh Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia. 2020. 6–7 p.
21. Oliveira O, Gaio R, Correia-Neves M, Rito T, Duarte R. Evaluation of drug-resistant tuberculosis treatment outcome in Portugal, 2000–2016. *PLoS One*. 2021;1–13.
22. Soeroto AY, Lestari BW, Santoso P, Chaidir L, Andriyoko B, Alisjahbana B, et al. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study. *PLoS One*. 2022;1–16.
23. Mokhena T, Mochane M, Tshwafo M, Linganiso L, Thekiso O, Songca S. The mutations of *katG* and *inhA* genes of isoniazid. *Intech*. 2016;225–40.
24. Singh R, Dwivedi SP, Gaharwar US, Meena R, Rajamani P, Prasad T. Recent updates on drug resistance in *Mycobacterium tuberculosis*. *J Appl Microbiol*. 2020;128(6):1547–67.
25. Allué-Guardia A, García JI, Torrelles JB. Evolution of Drug-Resistant *Mycobacterium tuberculosis* Strains and Their Adaptation to the Human Lung Environment. *Front Microbiol*. 2021;12(2):1–21.
26. Liang L, Wu Q, Gao L, Hao Y, Liu C, Xie Y, et al. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: A study from China. *Thorax*. 2012;67(7):632–8.

27. Xi Y, Zhang W, Qiao R, Tang J. Risk factors for multidrug-resistant tuberculosis : A worldwide systematic review and meta-analysis. 2022;1–15.
28. Resident E, Author C. Prevalence of Co morbidities among patients having Multi Drug Resistant Tuberculosis: A Retrospective Analysis. 2018;06(04):1029–32.
29. Ali A, Jaber S, Ibrahim B. Evaluation of risk factors associated with drug-resistant tuberculosis in Yemen : data from centres with high drug resistance. 2019;1:1–9.
30. Care P, Singh A, Prasad R, Balasubramanian V, Gupta N. Drug-Resistant Tuberculosis and HIV Infection : Current Perspectives. 2020;9–31.
31. Park M, Satta G, Kon OM. An update on multidrug-resistant tuberculosis. Clin Med (Northfield Il). 2019;19(2):135–9.
32. Khan I, Ahmad N, Khan S, Muhammad S, Ahmad Khan S, Ahmad I, et al. Evaluation of treatment outcomes and factors associated with unsuccessful outcomes in multidrug resistant tuberculosis patients in Baluchistan province of Pakistan. J Infect Public Health. 2019;12(6):809–15.
33. Farida F. Faktor keberhasilan pengobatan Multi Drug Resistance Tuberculosa (MDR-TB) di Indonesia : Tinjauan Sistematis. J Heal Epidemiol Commun Dis. 2020;6(1):33–9.
34. Malangu N, Ibrahim MO. Tuberculosis treatment outcomes in patients with resistant tuberculosis at a district hospital in Kwazulu-Natal Province of South Africa. 2014;28(1):51–62.
35. E. Elliott, 1 H. R. Draper, 2 P. Baitsiwe 3 M. M. Claassens2. Public Health Action Campaign. Public Heal Action. 2022;12(1):590-5.
36. Nowiński A, Wesółowski S, Korzeniewska-kosęła M. The impact of comorbidities on tuberculosis treatment outcomes in Poland : a national cohort study. 2023;(9):1–12.

37. Hayward SE, Deal A, Rustage K, Nellums LB, Sweetland AC, Boccia D, et al. The relationship between mental health and risk of active tuberculosis : a systematic review. 2022;13(6):890-15
38. Lasebikan VO, Ige OM. Prevalence of psychosis in tuberculosis patients and their nontuberculosis family contacts in a multidrug treatment-resistant treatment center in Nigeria. *Gen Hosp Psychiatry*. 2015;37(6):542–7.
39. Meressa D, Hurtado RM, Andrews JR, Diro E, Abato K, Daniel T, et al. Achieving high treatment success for multidrug- resistant TB in Africa : initiation and scale-up of MDR TB care in Ethiopia — an observational cohort study. 2015;1181–8.
40. Chung C, Shin JE, Jeon D, Kang H, Yim J, Jo K. Early View Treatment outcomes of multidrug-resistant tuberculosis with chronic kidney / liver disease. 2022;82-89.
41. Yusupova S, Nurullayeva S, Sadikov U, Gadoev J, Alikhanova N, Zachariah R, et al. Characteristics and Treatment Outcomes of New Pulmonary Tuberculosis Patients with Comorbidities in the Samarkand Region, Uzbekistan. In 2016.(1):1-116.
42. Urbanowski ME, Ordonez AA, Ruiz-Bedoya CA, Jain SK, Bishai WR. Cavitory tuberculosis: the gateway of disease transmission. *Lancet Infect Dis*. 2020;20(6):117–28.
43. Huang L, Jiang L, Lai Y, Wu M, Chang S. Pulmonary tuberculous cavities in diabetic patients : Glycemic control is still the dominant factor despite the emerging role of metformin. *J Chin Med Assoc*. 2019;628–34.
44. Dahlan MS. Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan Edisi 3. Seri evidence based medicine 2. Jakarta Salemba Medika Vol. 1. 2010. h 46–55.
45. Nuttall FQ. Body Mass Index: Obesity, BMI, and Health: A Critical Review.

Nutr Today. 2018 May;50(3):117–28.

46. Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Pelayanan Kedokteran : Tatalaksana Tuberkulosis. 2020. h 15–36.
47. Damayanti K. Hasil Akhir Pengobatan TB MDR dan Faktor-Faktor yang mempengaruhi di RSUP Persahabatan. 2018. h 35–54.
48. World Health Organization (WHO). Global Tuberculosis Report 2023. Geneva; 2023. 23–29 p.
49. Kesehatan K, Indonesia R. Laporan Program Penanggulangan Tuberkulosis Tahun 2021. 2021. h 36–40.
50. Bwire GM, Sambayi G, Maganda BA, Njiro BJ. JAC- Antimicrobial Resistance Clinical characteristics and treatment outcomes of patients with MDR tuberculosis in Dar Es Salaam region , Tanzania. 2020;1–8.
51. Rajendran M, Zaki RA, Aghamohammadi N. Contributing risk factors towards the prevalence of multidrug-resistant tuberculosis in Malaysia : A systematic review. Tuberculosis. 2020;122(3):119–25.
52. Id EM, Davidaviciene E, Kancauskiene Z, Diktanas S, Kausas A, Velyvyte D, et al. PLOS ONE The socio-demographic, clinical characteristics and outcomes of tuberculosis among HIV infected adults in Lithuania : A thirteen-year analysis. 2023;1–17.
53. Basu R, Kundu S, Biswas D, Nath S, Sarkar A, Bhattacharya A. Socio-Demographic and Clinical Profile of Drug Resistant Tuberculosis Patients in a Tertiary Care Centre of Kolkata. 2021;33(4):608–14.
54. Tao N-. Risk factors for drug- - resistant tuberculosis , the association between resistant comorbidity status and drug- - patterns : a retrospective study of previously treated pulmonary tuberculosis in Shandong , China , during 2004 – 2019. 2021;1–9.
55. Song W, Guo J, Xu T, Li S, Liu J, Tao N, et al. Association between body

mass index and newly diagnosed drug - resistant pulmonary tuberculosis in Shandong , China from 2004 to 2019. 2021;1–14.

56. Admassu F, Abera E, Gizachew A, Sedoru T. Risk factors of multidrug resistant tuberculosis among patients with tuberculosis at selected multidrug resistance treatment initiative centres in southern Ethiopia : a case- - control study. 2023;1–6.
57. Khan FU, Rehman A, Khan FU, Hayat K. Assessment of Factors Associated with Unfavorable Outcomes among Drug-Resistant TB Patients : A 6-Year Retrospective Study from Pakistan. 2022;1–13.
58. Iradukunda A, Ndayishimiye GP, Sinarinzi D, Odjidja EN, Ntakaburimvo N, Nshimirimana I, et al. Key factors influencing multidrug-resistant tuberculosis in patients under anti-tuberculosis treatment in two centres in Burundi: a mixed effect modelling study. 2021;1–9.
59. Adhanty S, Syarif S. Kepatuhan Pengobatan pada Pasien Tuberkulosis dan Faktor- Faktor yang Mempengaruhinya : Tinjauan Sistematis. 2023;7(1):7–14.
60. Song W, Li Y, Ma X, Liu J, Tao N, Liu Y, et al. Primary drug resistance of mycobacterium tuberculosis in Shandong , China , 2004 – 2018. 2019;1–12.
61. Bhering M. Primary and acquired multidrug-resistant tuberculosis : Predictive factors for unfavorable treatment outcomes in Rio de Janeiro , 2000 – 2016. 2020;1–10.
62. Jang JG, Chung JH. Diagnosis and treatment of multidrug-resistant tuberculosis. 2020;37(4):277–85.
63. Van LH, Phu PT, Vinh DN, Son VT, Hanh NT, Thanh L, et al. Risk factors for poor treatment outcomes of 2266 multidrug-resistant tuberculosis cases in Ho Chi Minh City : a retrospective study. 2020;1–10.
64. Karan Varshney, Beverly Anaele, Matthew Molaei, Rosemary Frasso VM.

Risk Factors for Poor Outcomes Among Patients with Extensively Drug-Resistant Tuberculosis (XDR-TB): A Scoping Review. 2021;5429–48.

65. Brust JCM, Gandhi NR, Carrara H, Osburn G, Padayatchi N. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. *Int J Tuberc Lung Dis*. 2010 Apr;14(4):413–9.
66. Hernandez GN, Seffah K, Zaman MA, Awais N, Satnarine T. Unraveling the Secrets Behind the Multidrug-Resistant Tuberculosis Treatment Outcome in Chronic Renal Failure Patients Requiring Hemodialysis : A Systematic Review *Methods*. 2023;15(3):1–14.
67. Reis-Santos B, Gomes T, Horta BL, Maciel ELN. The outcome of tuberculosis treatment in subjects with chronic kidney disease in Brazil: a multinomial analysis. *J Bras Pneumol*. 2013;39(5):585–94.
68. Anderson LF, Tamne S, Watson JP, Cohen T, Mitnick C, Brown T, et al. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. *Euro Surveill*. 2013 Oct;18(40).
69. Pedersen OS, Butova T, Kapustnyk V, Miasoiedov V, Kuzhko M, Hryshchuk L, et al. Treatment outcomes and risk factors for an unsuccessful outcome among patients with highly drug-resistant tuberculosis in Ukraine. *Clin Microbiol Infect*. 2024;30(3):360–7.
70. Starshinova A, Nazarenko M, Belyaeva E, Chuzhov A, Osipov N, Kudlay D. Assessment of Comorbidity in Patients with Drug-Resistant Tuberculosis. 2023;1–13.
71. Jakimova MA, Karpina N, Gordeeva O, Asanov R. Comorbidity : pulmonary tuberculosis and chronic obstructive pulmonary disease. 2019;296–9.
72. Nuwagira E, Stadelman A, Baluku JB, Rhein J, Byakika-kibwika P, Mayanja

- H, et al. Obstructive lung disease and quality of life after cure of multi-drug-resistant tuberculosis in Uganda : a cross-sectional study. 2020;48–55.
73. Trivedi P, Id VC. Interactive effect of oral anti-hyperglycaemic or anti – hypertensive drugs on the inhibitory and bactericidal activity of first line anti-TB drugs against *M. tuberculosis*. 2023;1–19.
74. Aaina M, Venkatesh K, Usharani B, Anbazhagi M, Rakesh G, Muthuraj M. Risk Factors and Treatment Outcome Analysis Associated with Second-Line Drug-Resistant Tuberculosis. 2022;1–12.
75. Cáceres G, Calderon R, Ugarte-gil C. Tuberculosis and comorbidities : treatment challenges in patients with comorbid diabetes mellitus and depression. 2022;1–17.
76. Pradipta IS, Bovencind-vrubleuskaya N Van, Akkerman OW, Alffenaar JC, Hak E. Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005 – 2015. 2019;1–12.
77. Kim S, Shin YM, Yoo JY, Cho JY, Kang H, Lee H, et al. Clinical Factors Associated with Cavitory Tuberculosis and Its Treatment Outcomes. 2021;9–12.
78. Lalor MK, Greig J, Allamuratova S, Althomsons S, Tigay Z, Khaemraev A, et al. Risk Factors Associated with Default from Multi- and Extensively Drug-Resistant Tuberculosis Treatment , Uzbekistan : A Retrospective Cohort Analysis. 2019;8(11).
79. Tang S, Tan S, Yao L, Li F, Li L, Guo X, et al. Risk Factors for Poor Treatment Outcomes in Patients with MDR-TB and XDR-TB in China : Retrospective Multi- Center Investigation. 2019;8(12):1–8.
80. Debash H, Nega J, Bisetegn H, Tesfaw G, Feleke DG, Ebrahim H, et al. Tuberculosis Treatment Outcomes and Its Predictors among Tuberculosis Patients Registered at Tefera Hailu Memorial General Hospital , Sekota

- Town , Northeast Ethiopia : A Seven-Year Retrospective Study. 2023;421–30.
81. July Mary Johnson, Aswini Kumar Mohapatra, Saleena Ummer Velladath KSS. Predictors of Treatment Outcomes in Drug Resistant Tuberculosis-Observational Retrospective Study. 2022;38–46.
82. Ma J, Zeng L, Ren F, Dang L, Luo H, Wu Y, et al. Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi ' an Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi ' an China , a Retrospective Cohort Study. 2022;447–57.
83. Ma J, Zeng L, Ren F, Dang L, Luo H, Wu Y, et al. Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi ' an China , a Retrospective Cohort Study. 2022;(8):4947–57.
84. Ji Lecai, Peierdun Mijiti, Hong Chuangyue GQ, Tan Weiguo CJ. Treatment outcomes of multidrug-resistant tuberculosis patients receiving ambulatory treatment in Shenzhen , China : a retrospective cohort study. 2023;(6):1–9.
85. Karnan A, Jadhav U, Ghewade B, Ledwani A, Shivashankar P. A Comprehensive Review on Long vs . Short Regimens in Multidrug-Resistant Tuberculosis (MDR-TB) Under Programmatic Management of Drug-Resistant Tuberculosis (PMDT). 2024;16(1):1–12.
86. Abidi S, Achar J, Mohamed M, Neino A, Bang D, Benedetti A, et al. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis, 2019(7):55–68.
87. Res JM, Zhang MW, Zhou L, Zhang Y, Chen B, Peng Y, et al. Treatment outcomes of patients with multidrug and extensively drug - resistant tuberculosis in Zhejiang , China. Eur J Med Res. 2021;1–10.
88. Khan MA, Mehreen S, Basit A, Khan RA, Jan F, Ullah I, et al. multi-drug resistant tuberculosis at a tertiary care hospital. 2019;36(12):1463–71.

89. Id JBF, Mendez D, Marais BJ, Peniyamina D. Predictors of unfavourable treatment outcome in patients diagnosed with drug- resistant tuberculosis in the Torres Strait / Papua New Guinea border region. 2022;1–15.
90. Widyasrini ER, Probandari AN. Factors Affecting the Success of Multi Drug Resistance (MDR-TB) Tuberculosis Treatment in Residential Surakarta. 2019;45–57.

